The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.

The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.  

When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.

Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.